Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G Kisses Pharma Biz Goodbye In $3.1B Deal With Warner Chilcott

Executive Summary

Warner Chilcott's $3.1 billion acquisition of Proctor & Gamble's pharmaceuticals business on Aug. 24 significantly bolsters the Irish drug maker's sales force and adds to its already lucrative women's health portfolio with the addition of Asacol HD and Actonel,while freeing P&G to focus on consumer health

You may also be interested in...

Actonel Delayed-Release Back On Track With New PDUFA Date In October

Three-month extension clarifies regulatory outlook for Warner Chilcott's once-weekly successor to osteoporosis blockbuster Actonel.

Warner Chilcott Transformation Underway With Integration Of P&G's Pharma Biz

With the acquisition of Procter & Gamble's pharma business complete, the specialty drug maker adds 1,900 employees.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009

Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts